JP6619332B2 - ヒトezh2遺伝子中の変異を検出するための方法及び組成物 - Google Patents
ヒトezh2遺伝子中の変異を検出するための方法及び組成物 Download PDFInfo
- Publication number
- JP6619332B2 JP6619332B2 JP2016516945A JP2016516945A JP6619332B2 JP 6619332 B2 JP6619332 B2 JP 6619332B2 JP 2016516945 A JP2016516945 A JP 2016516945A JP 2016516945 A JP2016516945 A JP 2016516945A JP 6619332 B2 JP6619332 B2 JP 6619332B2
- Authority
- JP
- Japan
- Prior art keywords
- ezh2
- nucleic acid
- oligonucleotide
- detecting
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361888660P | 2013-10-09 | 2013-10-09 | |
| US61/888,660 | 2013-10-09 | ||
| PCT/EP2014/071372 WO2015052147A1 (en) | 2013-10-09 | 2014-10-07 | Methods and compositions for detecting mutation in the human ezh2 gene |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533708A JP2016533708A (ja) | 2016-11-04 |
| JP2016533708A5 JP2016533708A5 (enExample) | 2017-11-16 |
| JP6619332B2 true JP6619332B2 (ja) | 2019-12-11 |
Family
ID=51663175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516945A Active JP6619332B2 (ja) | 2013-10-09 | 2014-10-07 | ヒトezh2遺伝子中の変異を検出するための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10260102B2 (enExample) |
| EP (1) | EP3055422B1 (enExample) |
| JP (1) | JP6619332B2 (enExample) |
| CN (1) | CN105593378B (enExample) |
| CA (1) | CA2923706C (enExample) |
| ES (1) | ES2705573T3 (enExample) |
| WO (1) | WO2015052147A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10260102B2 (en) | 2013-10-09 | 2019-04-16 | Roche Molecular Systems, Inc. | Methods and compositions for detecting mutation in the human EZH2 gene |
| KR102497728B1 (ko) | 2014-06-17 | 2023-02-09 | 에피자임, 인코포레이티드 | 림프종 치료를 위한 ezh2 억제제 |
| EP3310372A4 (en) * | 2015-05-19 | 2019-03-06 | Mayo Foundation For Medical Education And Research | METHOD AND MATERIALS FOR PROMOTING BONE TRAINING |
| EP3674709A1 (en) | 2015-11-05 | 2020-07-01 | Epizyme Inc | Flow cytometry for monitoring histone h3 methylation status |
| US11951108B2 (en) * | 2016-01-29 | 2024-04-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| WO2018076060A1 (en) | 2016-10-26 | 2018-05-03 | Genea Ip Holdings Pty Ltd | Improved generation of muscle lineage cells and therapeutic uses thereof |
| CN112226513B (zh) * | 2020-10-29 | 2022-02-01 | 华中科技大学 | 一种检测ezh2基因可变剪切位点突变的引物、试剂盒及应用 |
| CN119662835B (zh) * | 2025-02-20 | 2025-05-27 | 宁波熙宁检测技术有限公司 | 一种用于检测ezh2基因突变的核酸组合物、试剂盒及检测方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981176A (en) | 1992-06-17 | 1999-11-09 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
| DE69827060T2 (de) | 1997-03-20 | 2005-03-24 | F. Hoffmann-La Roche Ag | Modifizierte Primer |
| JP3937136B2 (ja) | 1999-12-10 | 2007-06-27 | 東洋紡績株式会社 | 塩基多型の検出方法 |
| US20060019256A1 (en) * | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| JP2009247231A (ja) | 2008-04-02 | 2009-10-29 | Olympus Corp | 標的塩基判別方法 |
| ES2527653T3 (es) | 2008-10-20 | 2015-01-28 | F. Hoffmann-La Roche Ag | Amplificación específica de alelo usando un cebador con un nucleótido modificado |
| US20100143901A1 (en) | 2008-12-09 | 2010-06-10 | Roche Molecular Systems, Inc. | Nuclease-Free Real-Time Detection of Nucleic Acids |
| CN101993934A (zh) * | 2009-08-10 | 2011-03-30 | 芮屈生物技术(上海)有限公司 | 一种ezh2基因的原位杂交检测试剂盒及其检测方法和应用 |
| CA2850570A1 (en) * | 2011-09-30 | 2013-04-04 | Glaxosmithkline Llc | Methods of treating cancer |
| WO2013086639A1 (en) * | 2011-12-14 | 2013-06-20 | British Columbia Cancer Agency Branch | Mutations indicative of weaver syndrome |
| US10260102B2 (en) | 2013-10-09 | 2019-04-16 | Roche Molecular Systems, Inc. | Methods and compositions for detecting mutation in the human EZH2 gene |
-
2014
- 2014-10-07 US US14/508,618 patent/US10260102B2/en active Active
- 2014-10-07 WO PCT/EP2014/071372 patent/WO2015052147A1/en not_active Ceased
- 2014-10-07 ES ES14781520T patent/ES2705573T3/es active Active
- 2014-10-07 EP EP14781520.3A patent/EP3055422B1/en active Active
- 2014-10-07 CN CN201480055312.0A patent/CN105593378B/zh active Active
- 2014-10-07 JP JP2016516945A patent/JP6619332B2/ja active Active
- 2014-10-07 CA CA2923706A patent/CA2923706C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2705573T3 (es) | 2019-03-26 |
| CA2923706C (en) | 2020-08-25 |
| JP2016533708A (ja) | 2016-11-04 |
| EP3055422A1 (en) | 2016-08-17 |
| CN105593378A (zh) | 2016-05-18 |
| US20150099747A1 (en) | 2015-04-09 |
| WO2015052147A1 (en) | 2015-04-16 |
| CA2923706A1 (en) | 2015-04-16 |
| EP3055422B1 (en) | 2018-11-14 |
| US10260102B2 (en) | 2019-04-16 |
| CN105593378B (zh) | 2019-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6619332B2 (ja) | ヒトezh2遺伝子中の変異を検出するための方法及び組成物 | |
| JP2014500028A (ja) | ヒト上皮成長因子受容体遺伝子内の突然変異を検出するための方法及び組成物 | |
| JP2012040029A (ja) | 変異の検出方法およびそれに用いるキット | |
| JP6453781B2 (ja) | ヒトpi3kca(pik3ca)遺伝子変異検出のための方法及び組成物 | |
| CN111212918A (zh) | 甲基化分析方法 | |
| US8377657B1 (en) | Primers for analyzing methylated sequences and methods of use thereof | |
| JP5602355B2 (ja) | 癌患者の外科的手術後の治療選択方法及び予後診断 | |
| JP6153758B2 (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット | |
| WO2023236201A1 (en) | Methods, compositions, and kits for detecting malignant lung nodules and lung cancer | |
| JP2022119753A (ja) | 高精度な遺伝子変異検出法 | |
| CN110964833B (zh) | 一种一管检测血浆游离dna中kras和braf基因突变的试剂盒 | |
| JP6205216B2 (ja) | 変異検出用プローブ、変異検出方法、薬効判定方法及び変異検出用キット | |
| US20130310550A1 (en) | Primers for analyzing methylated sequences and methods of use thereof | |
| JP4682275B2 (ja) | 哺乳動物の神経芽細胞腫の予後を判定する方法 | |
| JP2026500727A (ja) | 肺癌特異的メチル化マーカー遺伝子を用いた肺癌検出方法 | |
| CN120648795A (zh) | 用于检测卵巢病变的组合物及其用途 | |
| JPWO2011052754A1 (ja) | Egfr遺伝子多型検出用プローブおよびその用途 | |
| Cankovic | Laboratory Testing for Prognostic and Predictive |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20171004 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171004 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180820 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180911 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181211 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190709 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191009 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191015 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191114 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6619332 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |